Search

Your search keyword '"Lazrek, Mouna"' showing total 5 results
Start Over Author "Lazrek, Mouna" Topic infectious diseases
5 results on '"Lazrek, Mouna"'

1. Evaluation of the Genotypic Prediction of HIV-1 Coreceptor Use versus a Phenotypic Assay and Correlation with the Virological Response to Maraviroc: the ANRS GenoTropism Study

Author

Recordon-Pinson, Patricia, Soulié, Cathia, Flandre, Philippe, Descamps, Diane, Lazrek, Mouna, Charpentier, Charlotte, Montes, Brigitte, Trabaud, Mary-Anne, Cottalorda, Jacqueline, Schneider, Véronique, Morand-Joubert, Laurence, Tamalet, Catherine, Desbois, Delphine, Macé, Muriel, Ferré, Virginie, Vabret, Astrid, Ruffault, Annick, Pallier, Coralie, Raymond, Stéphanie, Izopet, Jacques, Reynes, Jacques, Marcelin, Anne-Geneviève, Masquelier, Bernard, Renseigné, Non, Microbiologie cellulaire et moléculaire et pathogénicité (MCMP), Université Bordeaux Segalen - Bordeaux 2-Centre National de la Recherche Scientifique (CNRS), CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de microbiologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Virology Laboratory, Hôpital Rothchild, Service de bactériologie-virologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Virology, Hôpital de la Timone [CHU - APHM] (TIMONE), Centre hospitalier universitaire de Nantes (CHU Nantes), Department of Human and Molecular Virology, Georges Clémenceau Universitary Hospital, Unité de Rétrovirologie, Hôpital Pontchaillou, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Laboratoire de virologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Bicêtre, Laboratoire de Virologie, Institut Fédératif de Biologie de Purpan, Variabilité génomique des virus, Université Bordeaux Segalen - Bordeaux 2-IFR66, Service de virologie et d'immunologie biologique, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Microbiologie Fondamentale et Pathogénicité (MFP), and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)

Subjects
Male, Oncology, MESH: Sequence Analysis, DNA, Multivariate analysis, HIV Infections, HIV Envelope Protein gp120, MESH: Receptors, CCR5, Maraviroc, MESH: Genotype, MESH: HIV-1, Correlation, MESH: HIV Envelope Protein gp120, chemistry.chemical_compound, HIV Protease, HIV Fusion Inhibitors, Genotype, MESH: Receptors, HIV, Pharmacology (medical), MESH: Treatment Outcome, 0303 health sciences, MESH: Middle Aged, MESH: Tropism, MESH: HIV Infections, Middle Aged, MESH: Cyclohexanes, HIV Reverse Transcriptase, 3. Good health, Phenotype, Treatment Outcome, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, Infectious Diseases, CCR5 Receptor Antagonists, Lentivirus, Female, Viral load, Adult, medicine.medical_specialty, Receptors, CCR5, MESH: HIV Reverse Transcriptase, Molecular Sequence Data, CCR5 receptor antagonist, Biology, MESH: Phenotype, Antiviral Agents, Sensitivity and Specificity, Tropism, MESH: HIV Protease, 03 medical and health sciences, Receptors, HIV, Cyclohexanes, Internal medicine, medicine, Humans, MESH: HIV Fusion Inhibitors, 030304 developmental biology, Pharmacology, MESH: Humans, MESH: Molecular Sequence Data, 030306 microbiology, MESH: Adult, Sequence Analysis, DNA, Triazoles, biology.organism_classification, Virology, MESH: Male, MESH: Sensitivity and Specificity, MESH: Triazoles, chemistry, Expanded access, HIV-1, MESH: Female
Abstract

Genotypic algorithms for prediction of HIV-1 coreceptor usage need to be evaluated in a clinical setting. We aimed at studying (i) the correlation of genotypic prediction of coreceptor use in comparison with a phenotypic assay and (ii) the relationship between genotypic prediction of coreceptor use at baseline and the virological response (VR) to a therapy including maraviroc (MVC). Antiretroviral-experienced patients were included in the MVC Expanded Access Program if they had an R5 screening result with Trofile (Monogram Biosciences). V3 loop sequences were determined at screening, and coreceptor use was predicted using 13 genotypic algorithms or combinations of algorithms. Genotypic predictions were compared to Trofile; dual or mixed (D/M) variants were considered as X4 variants. Both genotypic and phenotypic results were obtained for 189 patients at screening, with 54 isolates scored as X4 or D/M and 135 scored as R5 with Trofile. The highest sensitivity (59.3%) for detection of X4 was obtained with the Geno2pheno algorithm, with a false-positive rate set up at 10% (Geno2pheno10). In the 112 patients receiving MVC, a plasma viral RNA load of

Published
2010

2. A cohort study of treatment-experienced HIV-1-infected patients treated with raltegravir: factors associated with virological response and mutations selected at failure

Author

Marcelin, Anne-Geneviève, Delaugerre, Constance, Beaudoux, Céline, Descamps, Diane, Morand-Joubert, Laurence, Amiel, Corinne, Schneider, Veronique, Ferre, Virginie, Izopet, Jacques, Si-Mohamed, Ali, Maillard, Anne, Henquell, Cécile, Desbois, Delphine, Lazrek, Mouna, Signori-Schmuck, Anne, Rogez, Sylvie, Yerly, Sabine, Trabaud, Mary-Anne, Plantier, Jean-Christophe, Fourati, Slim, Houssaini, Allal, Masquelier, Bernard, Calvez, Vincent, Flandre, Philippe, Michelet, Christian, Epidémiologie, stratégies thérapeutiques et virologie cliniques dans l'infection à VIH, Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Génétique et Ecologie des Virus, Génétique des Virus et Pathogénèse des Maladies Virales, Université Paris Diderot - Paris 7 (UPD7)-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Virologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service de bactériologie-virologie, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), CHU Tenon [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre hospitalier universitaire de Nantes (CHU Nantes), Laboratoire de Virologie [Purpan], CHU Toulouse [Toulouse]-Institut Fédératif de Biologie (IFB) - Hôpital Purpan, Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse]-CHU Toulouse [Toulouse]-Hôpital Purpan [Toulouse], CHU Toulouse [Toulouse], CHU Pontchaillou [Rennes], Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Service de Bactériologie, Virologie, Hygiène [CHU Limoges], CHU Limoges, Laboratoire de virologie [Rouen], Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Département de microbiologie : Bactério, Virologie, Parasito, Hygiène-Hôpital Charles Nicolle [Rouen]-CHU Rouen, Normandie Université (NU), Service de virologie et d'immunologie biologique, CHU Bordeaux [Bordeaux]-Groupe hospitalier Pellegrin, Institut de recherche en santé, environnement et travail (Irset), Université d'Angers (UA)-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique ), ANRS AC11 Resistance Group, CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Laboratoire Virologie [CHU Toulouse], Institut Fédératif de Biologie (IFB), Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Pôle Biologie [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Hôpital Charles Nicolle [Rouen], CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-CHU Rouen, Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), and Université d'Angers (UA)-Université de Rennes (UR)-École des Hautes Études en Santé Publique [EHESP] (EHESP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Structure Fédérative de Recherche en Biologie et Santé de Rennes ( Biosit : Biologie - Santé - Innovation Technologique )

Subjects
Oncology, Male, Enfuvirtide, Etravirine, Pyrrolidinones/therapeutic use, HIV Infections, Integrase, Cohort Studies, chemistry.chemical_compound, 0302 clinical medicine, Antiretroviral Therapy, Highly Active, Medicine, Pharmacology (medical), 030212 general & internal medicine, Treatment Failure, ddc:616, 0303 health sciences, biology, Response, General Medicine, Viral Load, Resistance mutation, Pyrrolidinones, Antiretroviral Therapy, Highly Active/methods, 3. Good health, Infectious Diseases, [SDV.MP]Life Sciences [q-bio]/Microbiology and Parasitology, RNA, Viral, Female, Viral load, Mutations, medicine.drug, Microbiology (medical), medicine.medical_specialty, animal structures, Inhibitor, Efficacy, Anti-HIV Agents, Mutation, Missense, 03 medical and health sciences, Internal medicine, Raltegravir Potassium, Drug Resistance, Viral, Humans, RNA, Viral/blood, HIV Infections/drug therapy/virology, Darunavir, Maraviroc, 030306 microbiology, business.industry, Raltegravir, Virology, HIV-1/genetics/isolation & purification, CD4 Lymphocyte Count, chemistry, Anti-HIV Agents/therapeutic use, biology.protein, HIV-1, business
Abstract

International audience; This study aimed to identify factors associated with virological response (VR) to raltegravir (RAL)-containing regimens in 468 treatment-experienced but integrase inhibitor-naive HIV-1 patients receiving a RAL-containing regimen. VR was defined at Month 6 (M6) as HIV-1 RNA viral load (VL) 50 copies/mL at M6, integrase mutations selected were characterised. Median baseline VL was 4.2 log(10)copies/mL (IQR 3.3-4.9 log(10) copies/mL) and CD4 count was 219 cells/mm(3) (IQR 96-368 cells/mm(3)). At M6, 71% of patients were responders. In multivariate analysis, baseline VL and CD4 count and ≥ 2 new antiretrovirals among darunavir, etravirine, maraviroc and enfuvirtide were associated with VR to RAL. Neither HIV-1 subtype nor baseline integrase polymorphisms were associated with VR to RAL. Among 63 failing patients at M6, selection of ≥ 1 change in the integrase gene was observed in 49 (77.8%), and 27/63 (42.9%) were considered as RAL-associated resistance mutations. Factors independently associated with the occurrence of ≥ 1 RAL-associated resistance mutation were VL at failure >3 log(10) and having no new drugs associated with RAL. RAL showed great potency in treatment-experienced patients. The number of new drugs associated with RAL was an important factor associated with VR. HIV-1 subtype and baseline integrase polymorphisms do not influence the RAL VR.

Published
2013

3. Molecular and Clinical Characterization of Rotavirus From Diarrheal Infants Admitted to Pediatric Emergency Units in France

Author

De Rougemont , Alexis, Kaplon , Jérôme, Pillet , Sylvie, Mory , Olivier, Gagneur , Arnaud, Minoui-Tran , Adissa, Meritet , Jean-François, Mollat , Claudine, Lorrot , Mathie, Foulongne , Vincent, Gillet , Yves, Nguyen-Bourgain , Christelle, Alain , Sophie, Agius , Gérard, Lazrek , Mouna, Colimon , Ronald, Fontana , Caroline, Gendrel , Dominique, Pothier , Pierre, Renseigné , Non, Service de pédiatrie générale, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 ( UPD7 ), Biologie moléculaire et cellulaire des microorganismes ( EA3175 ), Université de Limoges ( UNILIM ) -Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST FR CNRS 3503 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université de Limoges ( UNILIM ), Département de Pédiatrie, Hôpital Saint Vincent de Paul, Laboratoire Interactions Muqueuses Agents Transmissibles ( LIMA ), Université de Bourgogne ( UB ), Laboratoire de sérologie-virologie (CHU de Dijon), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7), Biologie moléculaire et cellulaire des microorganismes (EA3175), Université de Limoges (UNILIM)-Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST FR CNRS 3503)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Limoges (UNILIM), Laboratoire Interactions Muqueuses Agents Transmissibles (LIMA), Université de Bourgogne (UB), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Université Paris Diderot - Paris 7 (UPD7)-Hôpital Robert Debré-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), and Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Robert Debré-Université Paris Diderot - Paris 7 (UPD7)

Subjects
Male, Rotavirus, Pediatric emergency, Pediatrics, viruses, medicine.disease_cause, Hospitals, University, Feces, fluids and secretions, Cluster Analysis, Antigens, Viral, 0303 health sciences, biology, Reverse Transcriptase Polymerase Chain Reaction, virus diseases, Gastroenteritis, 3. Good health, Hospitalization, Vaccination, Diarrhea, Infectious Diseases, Child, Preschool, [SDV.MP.VIR]Life Sciences [q-bio]/Microbiology and Parasitology/Virology, RNA, Viral, Female, France, medicine.symptom, Emergency Service, Hospital, Microbiology (medical), medicine.medical_specialty, Genotype, Molecular Sequence Data, Rotavirus Infections, Reoviridae, Context (language use), [ SDV.MP.VIR ] Life Sciences [q-bio]/Microbiology and Parasitology/Virology, 03 medical and health sciences, medicine, Animals, Humans, 030304 developmental biology, 030306 microbiology, business.industry, Infant, Sequence Analysis, DNA, Acute gastroenteritis, biology.organism_classification, Pediatrics, Perinatology and Child Health, Capsid Proteins, Cattle, business
Abstract

International audience; BACKGROUND:: Rotaviruses are the major cause of acute gastroenteritis in young children worldwide, and require careful surveillance, especially in the context of vaccination programs. Prospective surveillance is required to monitor and characterize rotavirus infections, including viral and clinical data, and to detect the emergence of potentially epidemic strains. METHODS:: Between 2006 and 2009, stool samples and clinical records were collected from 2044 children with acute diarrhea admitted to the pediatric emergency units of 13 French university hospitals. Rotaviruses were detected in stools, then genotyped by reverse transcription-polymerase chain reaction with regard to their outer capsid proteins VP4 and VP7. RESULTS:: The genotyping of 1947 rotaviruses showed that G1 (61.7%) and G9 (27.4%) strains were predominant and stable, followed by G2 (6.5%), G3 (4.0%), and G4 (2.5%) strains. Most strains were associated with P[8] (92.9%). Overall, 31 uncommon strains and possible zoonotic reassortants were detected including G12 and G8 strains, some being closely related to bovine strains. No difference in clinical presentation and severity was found among genotypes. CONCLUSIONS:: The relative stability of rotavirus genotypes currently cocirculating in France may ensure vaccine effectiveness in the short and medium term. However, the likely emergence of G12 and G8 strains should be monitored during ongoing and future vaccination programs, especially as all genotypes can cause severe infections. Special attention should be paid to the emergence of new rotavirus reassortants not included in current rotavirus vaccines.

Published
2010

4. In Vivo Persistence of Human Rhinoviruses in Immunosuppressed Patients.

Author

Engelmann, Ilka, Dewilde, Anny, Lazrek, Mouna, Batteux, Mathilde, Hamissi, Aminati, Yakoub-Agha, Ibrahim, and Hober, Didier

Subjects
RHINOVIRUSES, IMMUNOCOMPROMISED patients, ENTEROVIRUS diseases, VIRAL proteins, BLOOD diseases
Abstract

Several species of the genus Enterovirus cause persistent infections in humans. Human rhinovirus (HRV) infections are generally self-limiting but occasionally persistent infections have been described. This study aimed to identify persistent HRV infections and investigate the clinical and virologic characteristics of patients with persistent infections. From January 2012 to March 2015, 3714 respiratory specimens from 2608 patients were tested for respiratory viruses by using a multiplex reverse transcription–polymerase chain reaction. A retrospective study was performed. Patients with at least two specimens positive for HRV/enterovirus taken 45 days or longer apart were identified and the HRV/enteroviruses were typed. Patients with persistent infection were compared to patients with reinfection and patients with cleared infection. Phylogenetic analysis of the viral protein(VP)4/VP2 region was performed. 18 patients with persistent HRV/enterovirus infection were identified. Minimum median duration of persistence was 92 days (range 50–455 days). All but one patients with persistence were immunosuppressed. Immunosuppression and hematologic disorders were more frequent in patients with persistence (n = 18) than in patients with reinfection (n = 33) and with cleared infection (n = 25) (p = 0.003 and p = 0.001, respectively). In conclusion, this retrospective study identified HRV persistence in vivo which occurred mainly in immunosuppressed patients. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

5. In Vivo Persistence of Human Rhinoviruses in Immunosuppressed Patients

Author

Engelmann, Ilka, Dewilde, Anny, Lazrek, Mouna, Batteux, Mathilde, Hamissi, Aminati, Yakoub-Agha, Ibrahim, and Hober, Didier

Subjects
RNA viruses, Male, 0301 basic medicine, Viral Diseases, Time Factors, Pulmonology, Rhinovirus, medicine.medical_treatment, lcsh:Medicine, Pathology and Laboratory Medicine, medicine.disease_cause, Enteroviruses, Persistence (computer science), Database and Informatics Methods, Medicine and Health Sciences, Respiratory system, Young adult, lcsh:Science, Child, Respiratory Tract Infections, Phylogeny, Enterovirus, Multidisciplinary, Hematology, virus diseases, Phylogenetic Analysis, Immunosuppression, Coxsackieviruses, Middle Aged, Viral Persistence and Latency, Infectious Diseases, Medical Microbiology, Viral Pathogens, Child, Preschool, Viruses, RNA, Viral, Female, Pathogens, Sequence Analysis, Research Article, Adult, medicine.medical_specialty, Adolescent, Bioinformatics, Immunology, 030106 microbiology, Rhinovirus Infection, Research and Analysis Methods, Microbiology, Immune Suppression, Immunocompromised Host, Young Adult, 03 medical and health sciences, Signs and Symptoms, Diagnostic Medicine, Virology, Internal medicine, Enterovirus Infections, medicine, Humans, Molecular Biology Techniques, Molecular Biology, Microbial Pathogens, Aged, Retrospective Studies, Molecular Biology Assays and Analysis Techniques, Picornaviridae Infections, Biology and life sciences, business.industry, lcsh:R, Organisms, Infant, Newborn, Infant, Correction, Retrospective cohort study, Molecular Typing, Enterovirus Infection, 030104 developmental biology, Respiratory Infections, lcsh:Q, business, Sequence Alignment
Abstract

Several species of the genus Enterovirus cause persistent infections in humans. Human rhinovirus (HRV) infections are generally self-limiting but occasionally persistent infections have been described. This study aimed to identify persistent HRV infections and investigate the clinical and virologic characteristics of patients with persistent infections. From January 2012 to March 2015, 3714 respiratory specimens from 2608 patients were tested for respiratory viruses by using a multiplex reverse transcription–polymerase chain reaction. A retrospective study was performed. Patients with at least two specimens positive for HRV/enterovirus taken 45 days or longer apart were identified and the HRV/enteroviruses were typed. Patients with persistent infection were compared to patients with reinfection and patients with cleared infection. Phylogenetic analysis of the viral protein(VP)4/VP2 region was performed. 18 patients with persistent HRV/enterovirus infection were identified. Minimum median duration of persistence was 92 days (range 50–455 days). All but one patients with persistence were immunosuppressed. Immunosuppression and hematologic disorders were more frequent in patients with persistence (n = 18) than in patients with reinfection (n = 33) and with cleared infection (n = 25) (p = 0.003 and p = 0.001, respectively). In conclusion, this retrospective study identified HRV persistence in vivo which occurred mainly in immunosuppressed patients.

Catalog

Books, media, physical & digital resources
See catalog results